Desmopressin
Also known as: DDAVP, Nocdurna, Desmopressin acetate
Desmopressin is a longer-acting V2-selective vasopressin analog used for water-balance conditions and selected bleeding disorders. Excess water retention and low sodium are central safety concerns.
Quick Facts
Identity and receptor selectivity
Desmopressin acetate, marketed as DDAVP and Nocdurna, modifies the natural antidiuretic hormone vasopressin. Its structure extends activity and emphasizes water balance rather than vasopressin’s V1-mediated vasoconstriction. First US approval was in 1978.
Water channels and clotting-factor release
V2 activation in renal collecting ducts increases aquaporin-2 water channels, increasing water reabsorption and concentrating urine. Reduced V1 activity avoids the natural hormone’s blood-vessel constriction. A separate action releases stored factor VIII and von Willebrand factor from vascular-wall stores.
| Condition | Relevant action |
|---|---|
| Central diabetes insipidus | Restores water conservation when vasopressin is deficient. |
| Bedwetting or nocturnal polyuria | Reduces nighttime urine production. |
| Mild hemophilia A or type 1 von Willebrand disease | Releases stored clotting factors; bleeding uses employ higher exposures. |
Excess concentration/water retention can dilute serum sodium, which explains the major safety warning.
Products and prescribed uses
Desmopressin has been FDA-approved since 1978. Later nocturia products included Noctiva nasal spray (2017) and Nocdurna sublingual tablets (2018); Noctiva and Stimate nasal spray have since been discontinued in the US. Nocdurna carries a boxed hyponatremia warning, as Noctiva did.
Product/route-specific uses include central cranial diabetes insipidus, primary nocturnal enuresis, nocturia from nighttime overproduction of urine, and bleeding control in mild hemophilia A or type 1 von Willebrand disease. Formulations include oral, sublingual, nasal and injectable products. Fluid intake is managed carefully during treatment.
Sources: [1]
Adverse effects and sodium monitoring
Headache, nausea, flushing and nasal discomfort with spray are common effects. Severe hyponatremia can provoke seizures, explaining fluid restriction and the boxed warning. Fluid-overload risk and heart/kidney disease require particular caution.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- drugs.comProducts and prescribed usesCited in: Products and prescribed uses
Frequently Asked Questions About Desmopressin
Related Peptides
Continue exploring Desmopressin
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.